HemOnc.org - A Hematology Oncology Wiki - Recent changes [en]

← Older revision Revision as of 01:30, 22 August 2026 Line 8: Line 8:

{| class="wikitable" style="text-align:center; margin-left: auto; margin-right: auto; font-size:125%; font-weight: bold; width: 100%;"{| class="wikitable" style="text-align:center; margin-left: auto; margin-right: auto; font-size:125%; font-weight: bol...

← Older revision Revision as of 18:59, 21 August 2026 Line 570: Line 570: !style="width: 20%"|Comparative efficacy!style="width: 20%"|Comparative efficacy |-|- |[https://doi.org/10.1182/blood-2006-06-025999 Duvic et al. <time datetime="2006">2006</time>]|[https://doi.org/10.1182/blood-2006-06-025999 Duvic et al. <time ...

← Older revision Revision as of 12:29, 21 August 2026 Line 19: Line 19:

==History of changes in FDA indication====History of changes in FDA indication== *<time datetime="2006-10-06">October 6, 2006</time>: Initial FDA approval: treatment of cutaneous manifestations in patients with [[Cutaneous T-cell lymphoma...

PMDA indications for HER2+ breast cancer

← Older revision Revision as of 12:17, 21 August 2026 Line 72: Line 72: ==== PMDA indications for HER2+ breast cancer ======== PMDA indications for HER2+ breast cancer ==== *<time datetime="2020-03-25">March 25, 2020</time>: Conditional new approval for the treatment of unresectable...

History of changes in MFDS indication

← Older revision Revision as of 12:16, 21 August 2026 Line 9: Line 9: === History of changes in MFDS indication ====== History of changes in MFDS indication ===

* <time datetime="2023-07-12">July 12, 2023</time>: Newly approved as an orphan drug for the treatment of hemoly...